Table 3.
Tumor characteristics
| Characteristic | Surgery alone | Neoadjuvant therapy | Adjuvant therapy | Neoadjuvant & adjuvant therapy | Total | P value |
|---|---|---|---|---|---|---|
| Stage AJCC/TNM | 0.2092 | |||||
| IIA | 4 (26.7%) | 2 (22.2%) | 11 (27.5%) | 2 (22.2%) | 19 (26.0%) | |
| IIB | 10 (66.7%) | 3 (33.3%) | 25 (62.5%) | 7 (77.8%) | 45 (61.6%) | |
| III | 1 (6.7%) | 4 (44.4%) | 4 (10.0%) | 0 (0.0%) | 9 (12.3%) | |
| Location | 0.6592 | |||||
| Body | 1 (6.7%) | 2 (22.2%) | 2 (5.0%) | 1 (11.1%) | 6 (8.2%) | |
| Head | 12 (80.0%) | 7 (77.8%) | 34 (85.0%) | 8 (88.9%) | 61 (83.6%) | |
| Overlapping pancreas | 0 (0.0%) | 0 (0.0%) | 2 (5.0%) | 0 (0.0%) | 2 (2.7%) | |
| Tail | 2 (13.3%) | 0 (0.0%) | 2 (5.0%) | 0 (0.0%) | 4 (5.5%) | |
| Histological differentiation | 0.2742 | |||||
| Well | 1 (6.7%) | 2 (22.2%) | 4 (10.0%) | 1 (11.1%) | 8 (10.9%) | |
| Moderate | 8 (53.3%) | 7 (77.8%) | 27 (67.5%) | 6 (66.7%) | 48 (65.7%) | |
| Poor | 6 (40.0%) | 0 (0.0%) | 10 (25%) | 1 (11.1%) | 17 (23.2%) | |
| Lymph node positive | 0.0972 | |||||
| N0 | 7 (46.6%) | 4 (44.4%) | 11 (27.5%) | 2 (22.2%) | 24 (32.8%) | |
| N1 | 8 (53.3%) | 5 (55.6%) | 27 (67.5%) | 6 (66.7%) | 46 (63.0%) | |
| N2 | 0 (0.0%) | 0 (0.0%) | 2 (5.0%) | 1 (11.1%) | 3 (4.1%) | |
| Resection margins | 0.0512 | |||||
| R0 | 4 (26.7%) | 7 (77.8%) | 20 (50.0%) | 5 (55.6%) | 36 (49.3%) | |
| R1 | 3 (20.0%) | 0 (0.0%) | 12 (30.0%) | 4 (44.4%) | 19 (26.0%) | |
| R2 | 8 (53.3%) | 2 (22.2%) | 8 (20.0%) | 0 (0.0%) | 18 (24.6%) |
1
, ANOVA;
2
, Fisher’s Exact Test;
3
, Kruskal-Wallis Rank Sum Test.
AJCC/TNM 8th Ed. = American Joint Committee on Cancer/Tumor, Node, Metastasis Eight Edition; N, nodes, R, resection.